Overall Survival

Cell Mutations and Peritoneal Mesothelioma

Peritoneal mesothelioma is a hard cancer to treat because it is very aggressive and rare. It is usually found late due to it being rare and having unclear symptoms, making treatment very difficult. Current treatments that can include surgery and chemotherapy have limited success against the cancer. New ways to[…]

Read More »

New Biomarkers for Diagnosing Mesothelioma

Mesothelioma is a rare cancer linked to asbestos exposure that is dangerous for elderly Americans. It is hard to tell the difference between reactive and cancerous cells. This could be changed though due to a study in the American Journal of Pathology. The study identifies a key biomarker, ACADL, using[…]

Read More »

Advances in Immunotherapy for Mesothelioma

Malignant mesothelioma is a very rare cancer that often has a poor outlook in cancer treatment. Immunotherapy, especially in the form of immune checkpoint inhibitors, has brought hope. It shows the potential for better outcomes in mesothelioma patients. A new article in Open Respiratory Archives provides a history of recent[…]

Read More »

Carcinogenicity of Forsterite Compared to Asbestos

Mesothelioma, a rare cancer caused by asbestos, continues to be a global health issue. The most common form of asbestos is chrysotile. Recent research looked at chrysotile and a heat-treated form called forsterite. This research can help with safer asbestos disposal in the future. A recent study examined whether forsterite,[…]

Read More »

Immunotherapy Benefits and Drawbacks for Treating Mesothelioma

Mesothelioma is a rare and aggressive cancer that creates multiple challenges for patients and caregivers. Immune checkpoint inhibitors have recently shown promise to bring hope to people suffering from this devastating cancer. New data from Australia, however, is questioning their effectiveness and safety. Patients and caregivers must understand immunotherapy and[…]

Read More »

CRS and HIPEC for Peritoneal Mesothelioma

Peritoneal mesothelioma is a rare and aggressive cancer linked to asbestos exposure. A promising option for treating the cancer includes cytoreductive surgery (CRS) with heated chemotherapy (HIPEC). A new article explains cytoreductive surgery and HIPEC for the treatment of peritoneal mesothelioma. Cytoreductive surgery removes as many tumors as possible. In[…]

Read More »

Analysis of 70 Mesothelioma Cases

Malignant pleural mesothelioma is a severe cancer mainly caused by asbestos exposure. It often appears decades after exposure. Early on, symptoms can be unclear, making it difficult to diagnose. Even though the cancer is rare, a mesothelioma diagnosis is still concerning since there is a lack of treatment options. An[…]

Read More »

PORT-7 for the Treatment of Mesothelioma

Results from a clinical trial being performed on malignant pleural mesothelioma patients will be presented at the American Association for Cancer Research meeting being held in Chicago, Illinois. Results will be posted by internationally known mesothelioma expert Dr. Luciano Mutti of the department of Applied Clinical Sciences and Biotechnology at[…]

Read More »

Skip to content